116 3rd St SE
Cedar Rapids, Iowa 52401
KemPharm Appoints New COO
KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced the appointment of Gordon K. "Rusty" Johnson as Chief Operating Officer (COO) and Chief Financial Officer (CFO).
As COO and CFO of KemPharm, Mr. Johnson will join KemPharm's executive management team and will be responsible for enhancing the company's financial and operational initiatives and the ongoing development of KP201. KP201 is KemPharm's lead clinical candidate in development for the treatment of acute moderate to moderately severe pain. KemPharm anticipates submitting a new drug application (NDA) for KP201 to the FDA in the second quarter of 2014.
Daily Newsletters